Analysts Set Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) Price Target at $9.12

Key Points

• Autolus Therapeutics PLC has received an average recommendation of "Buy" from five analysts, with a 12-month target price of $9.12.
• Institutional investors have shown increased interest, with notable stake increases from firms like Virtus ETF Advisers and Barclays PLC.
• The stock has declined by 3.8% recently, trading at $1.78, despite reporting earnings of ($0.18) per share, surpassing analyst expectations.

Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) has been given a consensus recommendation of "Buy" by the five ratings firms that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have covered the stock in the last year is $9.12.

AUTL has been the subject of a number of analyst reports. Wall Street Zen raised shares of Autolus Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Needham & Company LLC reissued a "buy" rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, July 21st. Finally, Wells Fargo & Company reduced their price objective on shares of Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, August 13th.

Autolus Therapeutics Stock Performance

Shares of NASDAQ AUTL traded down $0.06 during midday trading on Friday, reaching $1.73. The stock had a trading volume of 2,410,336 shares, compared to its average volume of 2,752,232. The stock has a 50-day moving average of $2.29 and a 200-day moving average of $1.89. The company has a market capitalization of $460.42 million, a price-to-earnings ratio of -2.06 and a beta of 1.90. Autolus Therapeutics has a 12-month low of $1.1050 and a 12-month high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million during the quarter, compared to analysts' expectations of $12.92 million. As a group, analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Wellington Management Group LLP grew its stake in Autolus Therapeutics by 6.9% during the first quarter. Wellington Management Group LLP now owns 27,091,700 shares of the company's stock valued at $41,992,000 after acquiring an additional 1,746,020 shares in the last quarter. Armistice Capital LLC grew its stake in Autolus Therapeutics by 9.1% during the second quarter. Armistice Capital LLC now owns 12,000,000 shares of the company's stock valued at $27,360,000 after acquiring an additional 1,000,000 shares in the last quarter. TFG Asset Management GP Ltd grew its stake in Autolus Therapeutics by 10.5% during the second quarter. TFG Asset Management GP Ltd now owns 9,500,000 shares of the company's stock valued at $21,660,000 after acquiring an additional 900,000 shares in the last quarter. AXA S.A. purchased a new position in Autolus Therapeutics during the fourth quarter valued at $4,288,000. Finally, Millennium Management LLC grew its stake in Autolus Therapeutics by 91.6% during the fourth quarter. Millennium Management LLC now owns 1,653,241 shares of the company's stock valued at $3,885,000 after acquiring an additional 790,437 shares in the last quarter. 72.83% of the stock is owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.